BioCardia (NASDAQ: BCDA) CEO purchases 1,700 shares in open market

Rhea-AI Filing Summary

BioCardia, Inc. President and CEO Peter Altman bought additional company shares in the open market. He purchased 1,700 shares of common stock in an open-market transaction at a weighted average price of $1.758 per share.

After this purchase, his directly held ownership increased to 167,562 common shares. The trade was executed in multiple lots between $1.73 and $1.82 per share, with the reported price reflecting the weighted average.

Insider Trade Summary

Net Buyer: 1,700 shares ($2,989)

Net Buy 1 txn

Insider Altman Peter

Role President and CEO

Bought 1,700 shs ($3K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,700	$1.758	$3K

Holdings After Transaction: Common Stock — 167,562 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CA 94085

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2025		P		1,700(1)	A	$1.758(1)	167,562	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $1.73 to $1.82 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

	/s/ David McClung, by power of attorney	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioCardia (BCDA) report on this Form 4?

BioCardia reported that President and CEO Peter Altman bought 1,700 shares of common stock in an open-market transaction. The filing shows this was a routine purchase rather than a sale, increasing his directly held ownership stake in the company.

At what price did Peter Altman buy BioCardia (BCDA) shares?

Peter Altman bought 1,700 BioCardia shares at a weighted average price of $1.758 per share. The trades occurred in multiple lots between $1.73 and $1.82, with the reported figure representing the average purchase price across all executed transactions.

How many BioCardia (BCDA) shares does Peter Altman own after this transaction?

After this open-market purchase, Peter Altman directly owns 167,562 shares of BioCardia common stock. The Form 4 indicates these shares are held directly, reflecting his updated beneficial ownership following the 1,700-share acquisition reported in the filing.

Was the BioCardia (BCDA) insider transaction a buy or a sell?

The transaction was a buy. The Form 4 classifies it as an open-market purchase under transaction code “P,” meaning Peter Altman acquired additional BioCardia common shares rather than disposing of or selling any of his existing holdings.

How was the purchase price range disclosed for the BioCardia (BCDA) Form 4?

The filing notes the trade was executed in multiple transactions between $1.73 and $1.82 per share. The $1.758 figure reported is a weighted average, and the insider has undertaken to provide the exact breakdown of shares at each price upon request.